Schizophrenia

Schizophrenia symptoms, causes, and treatment: What you need to know

Schizophrenia is a psychiatric disorder affecting thought, perception, and behaviour. Key features include hallucinations, delusions, thought broadcasting, neologisms, echolalia, verbigeration, and thought blocking. It affects all demographics. Diagnosis involves imaging, and treatment includes psychosocial rehabilitation and pharmacological therapy

Study finds links between mental health conditions and career choices among individuals

The research, published in Nature Human Behaviour, examined 20 professional fields and identified clear patterns. Artists and designers were found to have the strongest predisposition to a range of mental health conditions, including bipolar disorder, schizophrenia, autism, depression, and anorexia.

World Mental Health Day 2024: 7 compelling films to watch and where to watch them

World Mental Health Day is observed globally on October 10 every year. Here is a list of films that you can watch on the day that explore myriad forms of mental health disorders through a humane lens.

World Schizophrenia Awareness Day 2024: How can patients live a normal life with other people

World Schizophrenia Awareness Day 2024: People with schizophrenia present most common symptoms such as hallucinations (Seeing, hearing, smelling, or feeling things that are not real), delusions, disorganised thoughts, unusual body movements and cognitive disorders.

World Schizophrenia Day 2024: Common myths and facts about this mental disorder

World Schizophrenia Day 2024: A lack of motivation, disordered thinking, and social disengagement are signs of this disorder. Here are few misconceptions related to schizophrenia. By busting these widespread misconceptions, we can advance a more realistic and caring viewpoint, promoting improved mental health services and lowering stigma.

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion

Under the terms of the deal, Bristol would pay $330 a share in cash for Karuna, which represents a 53.4% premium to its last closing price.

Deciphering schizophrenia: It's not easy to understand patient's delusions, but be patient with them

Schizophrenia often leads to delusions and hallucinations. You can support a patient deal with this challenging mental illness by validating their fears, encouraging them to express themselves and staying connected, and by recognising signs of danger.

World Mental Health Day 2023: The global burden of mental health disorders

On World Mental Health Day, October 10, know the data: pre-pandemic, in 2019, an estimated 970 million people in the world were living with a mental disorder; worldwide, 1 in 8 individual lives with a mental health condition, countries spend only 2 per cent of health budgets on treatment and prevention of mental health conditions.

China probes case of chained woman in shack after outcry

The woman's conditions were thrown under the spotlight after a blogger filmed a video in China's eastern Jiangsu province, showing him interviewing her in freezing weather.

Indian govt's schizophrenia led to COVID ravages: Amartya Sen

India was better placed to fight the pandemic because of its pharma manufacturing prowess and also higher immunity levels, the noted economist said while speaking at an event organised by the Rashtra Seva Dal late Friday evening.

Scientists identify brain activity pattern that may predict schizophrenia

The researchers followed 158 people between the ages of 13 and 34 who were identified as high-risk because they had experienced early symptoms.

Suven Life Sciences gets 1 product patent in India; shares up 3%

With this patent, the company has a total of 20 granted patents from India.

Suven Life Sciences shares up 5% on patents from Europe, Israel

Suven Life Sciences shares rallied more than 5 percent intraday Tuesday after getting patents from Europe and Israel.

Suven Life shares up 5% on patents in Canada, Europe & Hong Kong

With these new patents, Suven has a total of 24 granted patents from Canada, 22 from Europe and 21 from Hong Kong.

Suven Life gets patents for neurodegenerative drug

In a BSE filing, the company said it has been granted "two product patents from Canada and one product patent from China corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases." These patents are valid through 2029 and 2030, the company added.

Suven Life gets patents for neurodegenerative drug

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's

Suven Life Sciences gets patents for neurodegenerative drug

Biopharmaceutical firm Suven Life Sciences on Tuesday said it has been granted one patent each by the US, Israel and Macau for a drug used in the treatment of neurodegenerative diseases.

Suven Life Sciences gets patents for neurological drug

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's. In a BSE filing, the company said it has been granted "one product patent from Europe and one product patent from Hong Kong corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

Suven gets patents for neuro-degenerative disorder drug

With these new patents, Suven has a total of 21 granted patents from Australia, 15 from Europe, 16 from Hong Kong, four from Israel and five from Norway. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.